Mutations in the DNA mismatch repair gene MLH1 are a major cause of hereditary nonpolyposis colorectal cancer (HNPCC). No mutant phenotype is observed before the wild-type (wt) allele is somatically inactivated in target tissue. We addressed the mechanisms of MLH1 inactivation in 25 colorectal (CRC) and 32 endometrial cancers (ECs) from MLH1 mutation carriers (Mut1, in-frame genomic deletion; Mut2, out-of-frame splice site mutation; Mut3, missense mutation). By a quantitative method, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), utilizing four intragenic single nucleotide polymorphisms and mutations, loss of heterozygosity (LOH) was present in 31/57 (54.4%) of tumors. The wt allele displayed LOH more often than the mutant allele (23/57 vs 8/57, P ¼ 0.006). For Mut1, LOH was more frequent in CRC than EC (10/11 vs 1/13, Po0.0001), whereas Mut2 and Mut3 displayed opposite LOH pattern. Moreover, although wt LOH predominated in CRC irrespective of the predisposing mutation, LOH often affected the mutant allele in EC from Mut2 and Mut3 carriers (6/19, 31.6%). MLH1 promoter methylation, which reflected a more widespread hypermethylation tendency, occurred in 4/55 (7.3%) of tumors and was inversely associated with LOH. In conclusion, the patterns of somatic events (LOH and promoter methylation) differ depending on the tissue and germline mutation, which may in part explain the differential tumor susceptibility of different organs in HNPCC. MALDI-TOF provides a novel approach for the detection and quantification of LOH.
Introduction
According to Knudson's two-hit theory for tumor suppressor genes, dominantly inherited cancers and their sporadic counterparts are mechanistically linked. In the hereditary form, one mutation, the first 'hit', in a tumor suppressor gene is inherited, and the second 'hit' occurs in (and is limited to) the somatic cells of a target tissue. In the sporadic form, two 'hits', one in each allele, must occur somatically before tumor initiation (Knudson, 1971) .
DNA mismatch repair (MMR) genes whose mutations cause predisposition to hereditary nonpolyposis colorectal cancer (HNPCC) mainly act as tumor suppressor genes. MLH1 (MutL homolog 1) is the most important susceptibility gene for HNPCC (Peltomaki and Vasen, 2004) and also accounts for a major share of sporadic colorectal cancers (CRC) with microsatellite instability (MSI) (Kuismanen et al., 2000) . In HNPCCrelated CRCs, the residual wild-type (wt) allele is often silenced by loss of heterozygosity (LOH) (Tannergard et al., 1997; Kuismanen et al., 2000; Potocnik et al., 2001; Yuen et al., 2002) , whereas (biallelic) methylation of the MLH1 promoter primarily underlies sporadic microsatellite-unstable CRCs (Cunningham et al., 1998; Veigl et al., 1998; Kuismanen et al., 2000) . Considerably less data are available on the mechanisms of inactivation of the wt allele in HNPCC spectrum tumors other than CRC, notably endometrial cancer (EC) that is the most common extracolonic malignancy in HNPCC. In occasional EC tumors studied from HNPCC patients, LOH (for MSH2 and MSH6; Ollikainen et al., 2005) and somatic frameshift mutations (for MSH6; Wijnen et al., 1999) have been implicated. Sporadic EC resembles sporadic CRC, in that MLH1 promoter methylation appears to be the primary mechanism of MSI (Esteller et al., 1998; Simpkins et al., 1999) . In general, somatic point mutations rarely explain MMR gene inactivation in CRC (Tannergard et al., 1997; Kuismanen et al., 2000; Potocnik et al., 2001; Yuen et al., 2002) or EC (Chadwick et al., 2001) .
Recent observations suggest that the 'two-hit' theory represents a simplified model that may need re-evaluation. MMR gene mutations are not always dominant by the pattern of transmission, as exemplified by PMS2 (De Rosa et al., 2000) . On the cellular level, MMR gene mutations are not always recessive, but may have dominant-negative effects (Jager et al., 1997; Nicolaides et al., 1998) , or be associated with haploinsufficiency (Cejka et al., 2003; Takagi et al., 2003) . Furthermore, although initial studies suggested that all LOH events occurring in HNPCC tumors from MLH1 mutation carriers (6/6, 100%) affect the wt allele (Hemminki et al., 1994) , a recent investigation found that up to 40% (8/20) of LOH present in HNPCC CRC may target the mutant allele (Sanchez de Abajo et al., 2006) . The authors postulated a 'dual' role for LOH: although LOH may contribute to the inactivation of the wt allele ('second hit LOH'), it may also occur as part of tumor progression and affect the mutant allele in tumors in which the wt allele has already been inactivated by other means (Sanchez de Abajo et al., 2006) .
In HNPCC, it remains unsolved why different organs are differently susceptible to cancer under equal genetic predisposition, and the mechanisms of the wt allele inactivation might offer one possible explanation (de Wind et al., 1998) . We therefore examined a series of tumors from MLH1 germline mutation carriers to evaluate, first, the role of LOH and promoter methylation in HNPCC-associated CRC versus EC, and second, the applicability of a new methodological approach for LOH analysis, MassEXTEND analysis based on matrix assisted laser desorption/ionizationtime-of-flight mass spectrometry (MALDI-TOF MS).
Results
This investigation addressed the mechanisms of inactivation of MLH1, the most important susceptibility gene for HNPCC, by examining 25 colorectal and 32 endometrial tumors from 47 HNPCC patients for LOH and promoter methylation. All tumors showed lost MLH1 expression by immunohistochemistry. The respective individuals were carriers of one of three common MLH1 founding mutations in Finland (Mut1, Mut2 or Mut3) Nystrom-Lahti et al., 1996; Peltomaki et al., 2001) .
Loss of heterozygosity LOH at the MLH1 gene was studied by a quantitative method, MALDI-TOF, utilizing four intragenic single nucleotide substitutions (polymorphisms in the promoter region and exon 8 as well as Mut2 and Mut3). For a methodological control for MALDI-TOF, individuals heterozygous for the polymorphism in MLH1 exon 8 were independently investigated by a semi-quantitative primer extension-based method (SNuPE). For a targeted LOH analysis in carriers of Mut1 (a genomic deletion of exon 16), multiplex ligation-dependent probe amplification (MLPA) was used as our previous experience showed that MLPA was suitable to detect LOH in carriers of large genomic deletions (Zhang et al., 2006) .
The results for tumors showing LOH by MALDI-TOF analyses are shown in Table 1 , and the LOH data for all 57 tumors informative for MALDI-TOF (i.e. derived from individuals constitutionally heterozygous for at least one intragenic polymorphism or mutation) are summarized in Table 2. In addition to 30  tumors with LOH by MALDI-TOF, Table 2 includes a further tumor (colon tumor from individual 2:6) that showed LOH by MLPA only. LOH at the MLH1 gene was observed in 31/57 (54.4%) of all studied CRCs and ECs (Table 1 ). In tumors informative for several markers, LOH data obtained with the different markers were concordant, with a few exceptions (see below). Likewise, the MALDI-TOF and SNuPE results based on the exon 8 polymorphism were highly concordant (Table 3) .
Haplotype conservation associated with each ancestral founding mutation, as well as the nucleotide substitutions defining Mut2 and Mut3 per se, allowed us to determine if LOH affected the wt or the mutant allele in each case. In the entire series, the wt allele was the preferential target for LOH regardless of the tissue of origin or the predisposing mutation (23/57, 40.4% vs 8/57, 14.0%, for wt vs mutant allele LOH, respectively, P ¼ 0.006) ( Table 2 ). For Mut1, LOH was more common in CRC than EC (10/11 vs 1/13, Po0.0001), whereas for Mut2 and Mut3, LOH was more frequent in EC than CRC. Moreover, although wt LOH predominated in CRC irrespective of the predisposing mutation, wt and mutant allele LOH were roughly equally common in EC from Mut2 and Mut3 carriers (8/19 vs 6/19 for wt and mutant allele LOH, respectively, with the two mutations combined).
The extent of LOH in the 57 tumors included in the intragenic LOH analyses was assessed with six flanking microsatellite markers spanning an area of 4.3 Mb around MLH1 (see Materials and methods and Table 4 ). Among 20 informative tumors, LOH was restricted to MLH1 in eight (40%), whereas in the remaining 12 tumors (60%), LOH extended up to at least 2.5 Mb to the telomeric side of MLH1 (D3S1612) and 1.8 Mb to the centromeric side (D3S3521). Among 19 tumors informative for markers telomeric to MLH1, LOH was present in 11 (57.9%) and 2/7 (28.6%) tumors informative for markers centromeric to MLH1 showed LOH. Tumors without MLH1 LOH showed similar frequencies for surrounding LOH than those with MLH1 LOH, 5/8 (62.5%) for the telomeric region and 3/12 (25%) for the centromeric region (Table 4) . Regardless of the presence vs absence of intragenic LOH, it was possible to judge from the conserved haplotypes that all LOH events observed on the centromeric side (5/5) affected the wt allele, whereas a majority of those observed on the telomeric side (10/16) affected the allele carrying the predisposing mutation (Table 4 ). These data suggest that especially the region telomeric to MLH1 might harbor additional targets for LOH irrespective of MLH1.
Promoter methylation MLH1 promoter methylation was studied by a newly developed MS-MLPA assay that includes a CpG site adjacent to the start codon of MLH1. Methylation of this promoter region has been shown to result in MLH1 silencing. MLH1 promoter methylation occurred in 4/55 (7.3%) of tumors, and all four tumors were CRCs (MLPA analysis failed in two tumors included in LOH studies). MLH1 promoter methylation was more frequent in tumors without vs with LOH (3/23 vs 1/32) (Table 5 ). Moreover, in tumors without MLH1 LOH, promoter methylation was more common in CRC compared to EC (3/8 vs 0/15, P ¼ 0.03). The only tumor with both methylation and LOH (CRC from individual 26:15, Table 4 ) had lost the mutant allele, suggesting that methylation affected the wt allele. The same tumor harbored promoter methylation in altogether 11/24 tumor suppressor genes, suggesting a CpG island methylator phenotype (Toyota et al., 1999) . Analysis of all 24 tumor suppressor loci included in the assay All tumors displaying a reduction over 21% for one allele (i.e. having ratios below 0.8 or above 1.25) were regarded as having LOH, including 21 with 'strict LOH' (X40% reduction) and nine with 'putative LOH' (21-39% reduction; Ollikainen et al. (2005) ). ND, not determined. Table 4 shows the age at diagnosis, location and grade and stage of the tumors studied (according to Dukes classification for CRC (Dukes, 1932) , and FIGO classification for EC (Benedet et al., 2000) ). The average age of diagnosis was 48.6 years for CRC and 49.5 years for EC. Among CRCs, the LOH status at MLH1 did not correlate with the age of diagnosis. In contrast, ECs with wt LOH were diagnosed at a significantly earlier age (mean 43.2 years) compared to ECs with no LOH at MLH1 (mean 53.6 years; P ¼ 0.003) (ECs with mutant allele LOH were diagnosed at 47.5 years on average). MLH1 LOH status was not associated with tumor location in the colon, or with tumor grade or stage (for CRC or EC). For Mut1, LOH at MLH1 was more common in CRC than EC (Po0.0001, Table 2 ), whereas the average number of methylated loci was lower in CRC than EC (2.1 vs 3.1, statistically not significant). In contrast, for Mut2 and Mut3, LOH was more frequent in EC than CRC although not statistically significant (14/19 vs 6/14), and the average number of methylated loci was less frequent in EC than CRC (2.6 vs 5.8, P ¼ 0.017). ECs from Mut2 and Mut3 carriers showed more common LOH at MLH1 than those from Mut1 carriers (14/19 vs 1/13, P ¼ 0.0003, Table 2), and the same Mut2 and Mut3 ECs had lost their mutant allele relatively more frequently when compared to Mut1 ECs (7/19 vs 0/13, P ¼ 0.03). Thus, LOH appears to be an important determinant of tissue-specific cancer susceptibility and is inversely associated with a tendency to promoter hypermethylation of MLH1 and other tumor suppressor genes.
Discussion
Prompted by the incomplete understanding of the wt allele inactivation in tumors from MMR gene germline mutation carriers and the recent observation of frequent mutant allele LOH in HNPCC-CRC (Sanchez de Abajo et al., 2006), we chose to study LOH and promoter methylation in CRC and EC tumors from carriers of three ancestral founding mutations in MLH1. Our overall frequency for LOH at MLH1 (31/57, 54.4%) is compatible with frequencies reported for other series, mainly consisting of HNPCC-related CRCs (33-56%) (Kuismanen et al., 2000; Potocnik et al., 2001; Yuen et al., 2002; Sanchez de Abajo et al., 2006) . Our results show that the wt allele is the preferential target for LOH in both CRC and EC (P ¼ 0.006, Table 2 ). Expressed as a fraction of all observed LOH events, the frequency of mutant allele LOH was 2/16 (12.5%) for CRC, which is clearly lower than that (40%) reported by Sanchez de Abajo et al. (2006) . The relatively small sizes of the study series may in part explain this discrepancy. Mutant allele LOH accounted for a larger share of LOH in EC (6/15, 40%). Moreover, Sanchez de Abajo et al. (2006) found that the loss of the wt allele was associated with early age at diagnosis of CRC (below 50 years), and we observed a similar association for EC.
Our investigation shows that the MALDI-TOF method is suitable for the detection and quantification of LOH and is applicable to paraffin-derived DNA. Compared to polymorphic microsatellite markers, the MassEXTEND approach, which utilizes single nucleotide polymorphisms, may require a higher number of polymorphisms to obtain equally high heterozygosity values, but in the end, it is cheaper, has higher throughput and also works for tumors with high MSI. As with all polymerase chain reaction (PCR)-based methods, allele dropouts may pose a problem owing to low-quality DNA, and this might in turn falsely be interpreted as LOH. The problem of allele dropouts is, however, more pronounced when using microsatellite markers (Utsuno and Minaguchi, 2004; Petkovski et al., 2005; Dixon et al., 2006) . Consequently, the use of SNP markers as well as careful DNA quantification and genotyping multiple parallel samples should ensure reliable estimates of LOH. While our paper was in preparation, van Puijenbroek et al. (2005) published a study on the use of the MassEXTEND technique to examine LOH at the protein tyrosine phosphatase receptor type J locus in CRC, and these authors, too, concluded that 'MassEXTEND LOH analysis is a sensitive, high-throughput and cost-effective method to screen SNP loci for LOH in formalin-fixed paraffinembedded tissue'.
As shown in (Table 4) . One tumor (EC from 108:11) showed an isolated LOH in the promoter region only. Given that the degree of allelic loss was in the 'putative' range, this LOH event should be regarded with caution. Our observation of a frequent mutant allele LOH in the region telomeric to MLH1, in particular, implicated this region as a possible location of additional targets for LOH irrespective of MLH1. Potential target genes include DCAMKL3 (KIAA1765), which has doublecortin and CaM-kinase-like 3 motifs and may function in cell signaling (Nagase et al., 2000; Ohmae et al., 2006) , and STAC (SRC homology 3 and cysteine-rich domain), which may play a role in cell proliferation, transformation and apoptosis (Suzuki et al., 1996; Satoh et al., 2006) . The region at 3p21-22 is often deleted in human epithelial malignancies (Protopopov et al., 2003) , and future studies should examine if DCAMKL3 or STAC, or other genes from this region, are directly involved in these tumorigenic processes.
In addition to LOH, MLH1 promoter hypermethylation may serve as a second hit in HNPCC colorectal tumorigenesis. This is based on the observation of an inverse association between LOH and hypermethylation, indicating that a singly retained allele (which carries the germline mutation) is not hypermethylated, whereas in tumors with both alleles retained the wt copy occasionally is in 0-46% of tumors Kuismanen et al., 2000; Wheeler et al., 2000; Esteller et al., 2001; Potocnik et al., 2001) . The proportion of tumors showing MLH1 promoter methylation in the present study (4/55, 7.3%) was slightly lower than in some studies cited above, which may reflect the different regions of the MLH1 promoter studied, or different techniques or thresholds used to detect methylation. Our assay was designed to evaluate the MLH1 region D (Deng et al., 1999) , whose methylation, together with that of region C, shows the closest association with the lack of MLH1 protein expression (Deng et al. (1999) and our unpublished data). Although our overall figures are too small for any firm conclusions, the fact that MLH1 promoter methylation was more frequent in tumors without vs with MLH1 LOH (3/23 vs 1/32), and that in the single tumor with both LOH and methylation the mutant allele was lost, is compatible with the idea that MLH1 promoter methylation served as a second hit in these tumors. Our observation of tumors with MLH1 promoter methylation showing a significantly higher average number of other methylated tumor suppressor loci compared to those without MLH1 methylation (10/23 vs 3/23 methylated loci, Po0.0001) implied a more generalized hypermethylation tendency, with functional consequences on many other tumor suppressor genes besides MLH1.
In HNPCC, there is generally a poor correlation between the type of germline mutation (including the location and coding consequence) and clinical phenotype (Liu et al., 1996; Peltomaki et al., 2001) . In familial adenomatous polyposis, the germline mutation in APC may affect the type of the 'second hit' and these two hits together determine the phenotypic features (Albuquerque et al., 2002; Groves et al., 2002) . Moreover, mutations in tumor suppressor genes can have haploinsufficient phenotypes, and different functions (MMR vs activation of a damage checkpoint) may require different minimal dosages of the MLH1 protein (Cejka et al., 2003) . In our HNPCC series, either LOH or methylation served as second hits (i.e. affected the wt allele of MLH1) more frequently in CRCs when compared to ECs (18/25 vs 9/32, P ¼ 0.001), which might reflect different dosage requirements of MLH1 in these two tissues. The predisposing germline mutation could theoretically modulate this dosage sensitivity, for example, through variable degrees of residual protein activity. In the present tumors with Mut1, LOH was more common in CRC than EC, whereas Mut2 and Mut3 displayed opposite pattern (Table 2) ; the fact that the CRC to EC ratio is higher in families with Mut1 compared to those with Mut2 or Mut3 (our unpublished data) is in line with that. Collectively, the dependence of the patterns of LOH and methylation of tumor suppressor genes on tissue type and germline mutation as shown here may in part explain the differential tumor susceptibility of different organs in HNPCC.
Materials and methods
Patients and specimens A cohort of 86 patients, representing 37 Finnish HNPCC families, was selected on the basis of sample availability to be examined for constitutional heterozygosity (see section Loss of heterozygosity analysis). The final study cohort consisted of 25 CRCs and 32 ECs from 47 individuals, each being a carrier of one of three Finnish founding mutations in MLH1. Mut1 is an in-frame deletion (3.5 kb genomic deletion affecting codons 578-632 of exon 16 and flanking intron sequences), Mut2 is a frameshift mutation (g>a at 454-1 splice acceptor of exon 6) and Mut3 is a missense mutation (T>G at nucleotide 320 in exon 4, I107R). Mut1 and Mut2 together account for a majority of Finnish HNPCC kindreds meeting the international diagnostic criteria (Nystrom-Lahti et al., 1995) , and the pathogenicity of the missense mutation (Mut3) has been verified by functional tests (Raevaara et al., 2005) . The appropriate institutional review boards of the Helsinki University Central Hospital approved this study.
DNA extraction DNA was prepared from archival paraffin-embedded tumor and matching normal tissue samples according to the method of Isola et al. (1994) . Areas with high tumor percentages or with pure normal cells were selected and verified histologically and subsequently dissected out. Tumor percentages ranged between 50 and 95%.
Immunohistochemistry Formalin-fixed, paraffin-embedded tissue sections were immunohistochemically stained with anti-MLH1 (Pharmingen, San Diego, CA, USA; clone G168-15), anti-MSH2 (Calbiochem/ Oncogene Research, Darmstadt, Germany; clone FE-11) and anti-MSH6 (Transduction Laboratories, San Diego, CA, USA; clone 44). The DAKO EnVision þ System (Dako Cytomation, Glostrup, Denmark) was applied according to manufacturer's instructions with antigen retrieval step by microwave boiling for 10 min in ethylenediaminetetraacetic buffer (pH 8.0). Nuclear staining of normal endometrium and colorectum included in each tumor section were used as a reference for the evaluation of the staining results. These data were in part published in Schweizer et al. (2001) .
Loss of heterozygosity analysis Matrix-assisted laser desorption/ionization-time-of-flight. Normal (blood) DNA samples from 86 HNPCC patients were genotyped for two SNPs (MLH1 promoter G>A rs1800734 and MLH1 exon 8 G>A rs1799977) and 40.0 and 20.2% were heterozygous, respectively. Individuals heterozygous for either marker, or carrying one of two mutations (Mut2, Mut3), were selected for LOH analyses. MALDI-TOF was used to determine LOH at the MLH1 gene using those four intragenic SNPs and mutations mentioned above. The assays were calibrated using DNA samples with known genotypes (determined by sequencing). Based on titration experiments using the PicoGreen assay (Molecular Probes, Eugene, Oregon, USA), samples of 5 ng of DNA isolated from normal and tumor tissue of the patients were then subjected to MassEXTEND assay (Sequenom Inc., San Diego, CA, USA) as described in Supplementary methods at Oncogene's website. The SpectroCHIPS were analysed by an Autoflex MassARRAY mass spectrometer (Bruker Daltonics, Billerica, MA, USA). All samples were assayed at least in triplicate, and two persons performed the analysis independently. The allele frequency ratios for tumor samples were divided by the allele frequency ratio of the corresponding normal sample. The thresholds for LOH were defined according to Ollikainen et al. (2005) .
Single nucleotide primer extension The SNuPE analysis was based on the A>G polymorphism at nucleotide 655 in MLH1 exon 8 as described in Renkonen et al. (2003) . This assay relies on the incorporation of a single ddNTP that is chosen to allow the differential extension of a fluorescently labeled primer annealed next to the polymorphic site. Two fragments of different length are produced according to the base present at the polymorphic site. The primer extension products were separated by capillary electrophoresis (on ABI 3730 Automatic DNA sequencer, Applied Biosystems, Foster City, CA, USA) and analysed using Genemapper v4.0 (Applied Biosystems). Allelic dosages are determined from the peak areas of the fragments and their ratios in tumor DNA relative to normal DNA calculated.
Multiplex ligation-dependent probe amplification All samples carrying Mut1 (a genomic deletion of MLH1 exon 16) were examined for LOH using MLPA (SALSA MLPA-kit P003, MRC-Holland, Amsterdam, the Netherlands) according to the manufacturer's instructions (www.mrc-holland.com). The PCR products were separated by capillary electrophoresis and analysed using GeneMapper v4.0 (Applied Biosystems).
Microsatellite marker analysis The extent of LOH was studied by analysing the following microsatellite markers encompassing a 4.3-Mb region around MLH1: ptel-D3S1612-D3S3512-D3S3718-D3S1611 (MLH1)-D3S1298-D3S3521-cen. All primer sequences are available at www.ensembl.org/ Homo_sapiens/markerview. PCR products were run, electrophoresed and analysed as described above for SNuPE.
Methylation analysis
The MLPA method was applied using the SALSA MS-MLPA ME001 kit (MRC Holland, Amsterdam, the Netherlands) according to the manufacturer's instructions (www.mrcholland.com). MS-MLPA method relies on the disability of HhaI restriction enzyme to digest methylated target sequences, producing a signal after PCR amplification if the target site is methylated. The kit contains probe pairs for 24 tumor suppressor genes including two probes for the MLH1 gene.
Based on our titration experiments with cell lines known to have a full methylation (RKO) or a complete lack of methylation of MLH1 (HCT116) as well as on studies in which we correlated the methylation level and MLH1 protein expression by immunohistochemical analysis, a dosage ratio of 0.10 or higher at the CpG island adjacent to the translation start site of MLH1 (corresponding to 10% of methylated DNA) was regarded to indicate promoter methylation. A dosage ratio of 0.15 or higher was applied to the promoters of other tumor suppressor genes because this threshold value provided the best discrimination of tumor DNA relative to paired normal DNA where no methylation was expected.
Statistical analysis
The significance of differences between groups was evaluated with the Fisher's exact test or with the t-test. P-values below 0.05 (two-tailed) were interpreted to indicate statistical significance.
